Cargando…

FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment

BACKGROUND: Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of germline DNA. This project aimed to establish if normal FFPE breast tissue could be used...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkins, Anna, Chauhan, Ritika, Rust, Alistair, Pearson, Alex, Daley, Frances, Manodoro, Floriana, Fenwick, Kerry, Bliss, Judith, Yarnold, John, Somaiah, Navita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022520/
https://www.ncbi.nlm.nih.gov/pubmed/29700676
http://dx.doi.org/10.1007/s10549-018-4798-7
_version_ 1783335695674245120
author Wilkins, Anna
Chauhan, Ritika
Rust, Alistair
Pearson, Alex
Daley, Frances
Manodoro, Floriana
Fenwick, Kerry
Bliss, Judith
Yarnold, John
Somaiah, Navita
author_facet Wilkins, Anna
Chauhan, Ritika
Rust, Alistair
Pearson, Alex
Daley, Frances
Manodoro, Floriana
Fenwick, Kerry
Bliss, Judith
Yarnold, John
Somaiah, Navita
author_sort Wilkins, Anna
collection PubMed
description BACKGROUND: Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of germline DNA. This project aimed to establish if normal FFPE breast tissue could be used as an alternative to blood. METHODS: Exome sequencing was carried out on matched tumour tissue, normal breast tissue and blood on five patients in the START trial. Retrieved samples had been archived at different centres for at least 13 years. Following tissue macro-dissection and DNA extraction, targeted exome capture was performed using SureSelect Human All Exome v5 reagents (Agilent). Illumina paired-end libraries were prepared from the captured target regions and sequenced on a HiSeq2500 (Illumina) acquiring 2 × 75 bp reads. Somatic variants were called using the MuTect software analysis tool and copy number abnormalities (CNA) were identified using CNVkit. Targeted sequencing and droplet digital PCR were used to validate somatic variants and CNA, respectively. RESULTS: Overlap of somatic variants and CNA called on tumour versus blood and tumour versus normal breast tissue was good. Agreement in somatic variant calling ranged from 76.9 to 93.6%. Variants with an allele frequency lower than 10% were more difficult to validate irrespective of the type of germline DNA used. Pearson’s correlation coefficients for paired comparisons of CNA using blood or normal tissue as reference ranged from 0.70 to 0.94. CONCLUSIONS: There is good correlation between the somatic mutations and CNA called using archived blood or normal breast tissue as germline reference material. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10549-018-4798-7) contains supplementary material, which is available to authorised users.
format Online
Article
Text
id pubmed-6022520
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-60225202018-07-06 FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment Wilkins, Anna Chauhan, Ritika Rust, Alistair Pearson, Alex Daley, Frances Manodoro, Floriana Fenwick, Kerry Bliss, Judith Yarnold, John Somaiah, Navita Breast Cancer Res Treat Clinical Trial BACKGROUND: Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of germline DNA. This project aimed to establish if normal FFPE breast tissue could be used as an alternative to blood. METHODS: Exome sequencing was carried out on matched tumour tissue, normal breast tissue and blood on five patients in the START trial. Retrieved samples had been archived at different centres for at least 13 years. Following tissue macro-dissection and DNA extraction, targeted exome capture was performed using SureSelect Human All Exome v5 reagents (Agilent). Illumina paired-end libraries were prepared from the captured target regions and sequenced on a HiSeq2500 (Illumina) acquiring 2 × 75 bp reads. Somatic variants were called using the MuTect software analysis tool and copy number abnormalities (CNA) were identified using CNVkit. Targeted sequencing and droplet digital PCR were used to validate somatic variants and CNA, respectively. RESULTS: Overlap of somatic variants and CNA called on tumour versus blood and tumour versus normal breast tissue was good. Agreement in somatic variant calling ranged from 76.9 to 93.6%. Variants with an allele frequency lower than 10% were more difficult to validate irrespective of the type of germline DNA used. Pearson’s correlation coefficients for paired comparisons of CNA using blood or normal tissue as reference ranged from 0.70 to 0.94. CONCLUSIONS: There is good correlation between the somatic mutations and CNA called using archived blood or normal breast tissue as germline reference material. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10549-018-4798-7) contains supplementary material, which is available to authorised users. Springer US 2018-04-26 2018 /pmc/articles/PMC6022520/ /pubmed/29700676 http://dx.doi.org/10.1007/s10549-018-4798-7 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Clinical Trial
Wilkins, Anna
Chauhan, Ritika
Rust, Alistair
Pearson, Alex
Daley, Frances
Manodoro, Floriana
Fenwick, Kerry
Bliss, Judith
Yarnold, John
Somaiah, Navita
FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment
title FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment
title_full FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment
title_fullStr FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment
title_full_unstemmed FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment
title_short FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment
title_sort ffpe breast tumour blocks provide reliable sources of both germline and malignant dna for investigation of genetic determinants of individual tumour responses to treatment
topic Clinical Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022520/
https://www.ncbi.nlm.nih.gov/pubmed/29700676
http://dx.doi.org/10.1007/s10549-018-4798-7
work_keys_str_mv AT wilkinsanna ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment
AT chauhanritika ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment
AT rustalistair ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment
AT pearsonalex ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment
AT daleyfrances ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment
AT manodorofloriana ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment
AT fenwickkerry ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment
AT blissjudith ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment
AT yarnoldjohn ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment
AT somaiahnavita ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment